Showing results (581-590 of 3,716) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|May 1, 1991
Phase II evaluation of fludarabine phosphate in patients with central nervous system tumors. A Southwest Oncology Group trialS A Taylor, J Crowley, F S Vogel, et al.
Investigational New Drugs|July 20, 2007
Effects of dutasteride on the expression of genes related to androgen metabolism and related pathway in human prostate cancer cell linesMichela Biancolella, Alessandra Valentini, Daniela Minella, et al.
Investigational New Drugs|July 11, 2007
Cell growth inhibition, G2M cell cycle arrest, and apoptosis induced by the novel compound Alternol in human gastric carcinoma cell line MGC803Xia Liu, Jingze Wang, Bo Sun, et al.
Investigational New Drugs|July 14, 2007
INO-1001, a novel inhibitor of poly(ADP-ribose) polymerase, enhances tumor response to doxorubicinKathryn A Mason, David Valdecanas, Nancy R Hunter, et al.
Investigational New Drugs|July 14, 2007
Amrubicin for non-small-cell lung cancer and small-cell lung cancerTakayasu Kurata, Isamu Okamoto, Kenji Tamura, et al.
Investigational New Drugs|May 31, 2007
Targeting telomerase activity by BIBR1532 as a therapeutic approach in germ cell tumorsSandra Mueller, Ulrike Hartmann, Frank Mayer, et al.
Investigational New Drugs|May 24, 2007
Pomolic acid-induced apoptosis in cells from patients with chronic myeloid leukemia exhibiting different drug resistance profileF C Vasconcelos, C R Gattass, V M Rumjanek, et al.
Investigational New Drugs|May 10, 2006
Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignanciesCheryl D Cho, George A Fisher, Joanne Halsey, et al.
Investigational New Drugs|May 10, 2006
A phase I safety and dose escalation trial of docetaxel combined with GEM231, a second generation antisense oligonucleotide targeting protein kinase A R1alpha in patients with advanced solid cancersSanjay Goel, Kavita Desai, Manuel Macapinlac, et al.
Investigational New Drugs|April 25, 2006
Trabectedin (ET-743, Yondelis) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotypeJan-Hendrik Beumer, Tessa Buckle, Mariet Ouwehand, et al.
Pageof 372